· Periodic Report
Q3 operating loss of KRW 0.3 billion, swinging to a loss; revenue KRW 3.4 billion
Jeonjin Biopharm sold KRW 3.4 billion worth in Q3 but lost KRW 0.3 billion from its main business, turning from profit to loss versus a year earlier.
110020 · KOSDAQ · Based on DART filings
1 total · 20 per page
· Periodic Report
Jeonjin Biopharm sold KRW 3.4 billion worth in Q3 but lost KRW 0.3 billion from its main business, turning from profit to loss versus a year earlier.
Get app alerts for new disclosures from JEONJINBIO CO., LTD..